Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BJDX NASDAQ:MOTS NASDAQ:NVIV NASDAQ:SINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$1.50$1.65$1.46▼$37.50$2.24M0.4832,180 shs14,939 shsMOTSMotus GI$0.00$0.00$0.00▼$0.08$1K1.046,242 shs41,402 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsSINTSintx Technologies$2.40-4.0%$2.97$1.71▼$8.60$6.02M0.65233,805 shs66,663 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics0.00%-3.85%-9.37%-21.88%-93.75%MOTSMotus GI0.00%0.00%-66.67%0.00%-99.86%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%SINTSintx Technologies0.00%-14.29%-27.82%-13.36%-52.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBJDXBluejay Diagnostics1.1678 of 5 stars0.05.00.00.02.80.00.6MOTSMotus GIN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASINTSintx Technologies2.1763 of 5 stars3.52.00.00.01.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBJDXBluejay Diagnostics 0.00N/AN/AN/AMOTSMotus GI 0.00N/AN/AN/ANVIVInVivo Therapeutics 0.00N/AN/AN/ASINTSintx Technologies 3.00Buy$28.001,066.67% UpsideCurrent Analyst Ratings BreakdownLatest SINT, BJDX, MOTS, and NVIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025SINTSintx TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBJDXBluejay Diagnostics$250K8.94N/AN/A$10.34 per share0.15MOTSMotus GI$319K0.00N/AN/A$1.74 per share0.00NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ASINTSintx Technologies$2.89M2.08N/AN/A$2.90 per share0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBJDXBluejay Diagnostics-$7.72M-$379.74N/A∞N/AN/A-322.46%-262.96%8/13/2025 (Estimated)MOTSMotus GI-$12.87M-$15.64N/A∞N/AN/AN/AN/AN/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ASINTSintx Technologies-$11.02M-$50.56N/A∞N/A-483.85%-203.66%-104.76%8/4/2025 (Estimated)Latest SINT, BJDX, MOTS, and NVIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025N/ASINTSintx Technologies-$0.79N/AN/AN/AN/AN/A5/15/2025Q1 2025SINTSintx Technologies-$0.71-$1.29-$0.58-$1.29$0.73 million$0.37 million5/13/2025Q1 2025BJDXBluejay DiagnosticsN/A-$3.37N/A-$3.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBJDXBluejay DiagnosticsN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBJDXBluejay DiagnosticsN/A2.712.71MOTSMotus GIN/AN/AN/ANVIVInVivo TherapeuticsN/A14.3014.30SINTSintx TechnologiesN/A3.443.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBJDXBluejay Diagnostics18.47%MOTSMotus GI20.06%NVIVInVivo Therapeutics13.78%SINTSintx Technologies18.38%Insider OwnershipCompanyInsider OwnershipBJDXBluejay Diagnostics0.08%MOTSMotus GI0.34%NVIVInVivo Therapeutics2.45%SINTSintx Technologies0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBJDXBluejay Diagnostics91.49 million1.49 millionNot OptionableMOTSMotus GI305.77 million5.75 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableSINTSintx Technologies402.51 million2.51 millionNot OptionableSINT, BJDX, MOTS, and NVIV HeadlinesRecent News About These CompaniesSINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical DevicesJuly 22, 2025 | taiwannews.com.twTSintx Technologies, Inc. (SINT) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comSINTX Technologies Acquires Surgical Business Assets Of SiNAPTIC Holdings - NasdaqJune 26, 2025 | nasdaq.comSINTX Technologies stock jumps on deal to acquire SiNAPTIC surgical assetsJune 24, 2025 | msn.comSINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion MarketJune 24, 2025 | globenewswire.comMark Lewis Anderson Acquires 10,000 Shares of Sintx Technologies, Inc. (NASDAQ:SINT) StockJune 24, 2025 | insidertrades.comSINTX Technologies Announces Strategic Vision Focused on Expansion Across Key SectorsJune 13, 2025 | tmcnet.comSintx Technologies Draws Heavy Retail Buzz On New Patent Push, SubsidiaryMay 23, 2025 | msn.comSINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech MarketMay 22, 2025 | globenewswire.comSiNtx Technologies Inc.May 19, 2025 | marketwatch.comSiNtx Technologies Inc.May 19, 2025 | marketwatch.comSINTX Technologies, Inc.: SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device CommercializationMay 16, 2025 | finanznachrichten.deMark Lewis Anderson Purchases 5,000 Shares of Sintx Technologies, Inc. (NASDAQ:SINT) StockMay 15, 2025 | insidertrades.comSINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device CommercializationMay 15, 2025 | globenewswire.comSintx Technologies, Inc. (NASDAQ:SINT) Insider Gregg R. Honigblum Buys 10,000 SharesMay 1, 2025 | insidertrades.comSintx Technologies Appoints Five New Board DirectorsApril 8, 2025 | tipranks.comSintx Technologies announces changes to board, Chairman Bal to retireApril 5, 2025 | markets.businessinsider.comSINTX Technologies Announces Strategic Changes to Board of DirectorsApril 3, 2025 | markets.businessinsider.comSINTX: Peer-reviewed Study Shows Biomechanical Advantages Of Silicon Nitride In ACDF ProceduresMarch 21, 2025 | nasdaq.comMaxim Group Reaffirms Their Hold Rating on Sintx Technologies (SINT)March 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSINT, BJDX, MOTS, and NVIV Company DescriptionsBluejay Diagnostics NASDAQ:BJDX$1.50 0.00 (0.00%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$1.48 -0.02 (-1.33%) As of 08/1/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Motus GI NASDAQ:MOTS$0.0001 0.00 (0.00%) As of 08/1/2025 01:06 PM EasternMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.InVivo Therapeutics NASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Sintx Technologies NASDAQ:SINT$2.40 -0.10 (-4.00%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$2.36 -0.04 (-1.83%) As of 08/1/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
